Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Pflugfelder, Annette ^a   Eigentler, Thomas K ^a   Keim, Ulrike ^a   Weide, Benjamin ^a   Leiter, Ulrike ^a   Ikenberg, Kristian ^a   Berneburg, Mark ^a   Garbe, Claus ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SKIN TUMOR; SURVIVAL TIME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; COHORT ANALYSIS; EVALUATION; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951869389     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016882     Document Type: Article

References (21)

1. Cancer website. Available: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf. Accessed 2010.
2. Eggermont AM, Kirkwood JM, (2004) Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 40: 1825-1836.
3. Eigentler TK, Caroli UM, Radny P, Garbe C, (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4: 748-759.
4. Zamagni C, Martoni A, Cacciari N, Gentile A, Pannuti F, (1998) The combination of paclitaxel and carboplatin as first-line chemotherapy in patients with stage III and stage IV ovarian cancer: a phase I-II study. Am J Clin Oncol 21: 491-497.
5. Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, et al. (2008) Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 20;26: 468-473.
6. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, et al. (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 20;27: 1419-1425.
7. Einzig AI, Wiernik PH, Schwartz EL, (1991) Taxol: a new agent active in melanoma and ovarian cancer. Cancer Treat Res 58: 89-100.:89-100.
8. Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C, et al. (1996) Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 14: 2054-2060.
9. du BA, Neijt JP, Thigpen JT, (1999) First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer-a new standard of care? Ann Oncol 10 (Suppl 1): 35-41.:35-41.
10. Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, et al. (2008) A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 14: 4836-4842.
11. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, et al. (2009) Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma. J Clin Oncol 17: 2823-30.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
13. Kaplan EL, Meier P, (2009) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 53: 457-481.
14. Lee CW, Matulonis UA, Castells MC, (2005) Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 99: 393-399.
15. Bamias A, Deliveliotis C, Fountzilas G, Gika D, Anagnostopoulos A, et al. (2004) Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol 22: 2150-2154.
16. International Collaborative Ovarian Neoplasm Group (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360: 505-515.
17. Vaughn DJ, Manola J, Dreicer R, See W, Levitt R, et al. (2002) Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer 95: 1022-1027.
18. Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG, (2002) Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 25: 283-286.
19. Zimpfer-Rechner C, Hofmann U, Figl R, Becker JC, Trefzer U, et al. (2003) Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 13: 531-536.
20. Perez DG, Suman VJ, Fitch TR, Amatruda T, Morton RF, et al. (2009) Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 115: 119-127.
21. Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, et al. (2006) Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 106: 375-382.